Business Wire

Panasonic Fulfills 100 Thousand Solar Lanterns Project in Its 100th Anniversary, Bringing Light to Off-grid Communities Globally

Jaa

Panasonic Corporation announced the successful completion of its 100 Thousand Solar Lanterns Project, which has brought light to off-grid communities in 30 countries through 131 non-profit and other organizations in the last five years. Since the project's inception in February 2013, a total of 102,716 solar lanterns have been donated, including 5,004 lanterns given today to Indonesia, which has marked the end of the project.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180208005520/en/

Ikat tapestries, which are sold as handicraft goods, can be woven at night, to increase the income f ...

Ikat tapestries, which are sold as handicraft goods, can be woven at night, to increase the income for the Riangbaring Village in Indonesia. (Photo: Business Wire)

The project was part of Panasonic's Corporate Social Responsibility (CSR) initiatives that make use of its technologies and products in line with the company's management philosophy since its founding in 1918, that is, to make a contribution to the progress and development of society and the well-being of people through its business activities.

There are estimated 1.1 billion people who live without electricity in emerging and developing countries. Panasonic's project got started with the aim to help solve social issues stemming from a lack of light in the fields of medicine, education and economy, among others. Panasonic has strived towards the goal of donating a total of 100,000 units of solar lanterns by 2018, its centenary year.

Panasonic's lanterns, which were brought to communities in cooperation with non-profit, non-governmental and other international organizations, helped alleviate problems and brought about improvements in such areas as education, health and medicine, and women's independence. The solar lanterns have also contributed to the Sustainable Development Goals (SDGs) set by the United Nations to mobilize global efforts to end poverty, protect the planet and ensure prosperity.

With the completion of the 100 Thousand Solar Lanterns Project, Panasonic now carries on its efforts to deliver more light to people in regions without access to electricity in a new framework. In Japan, Panasonic employees took part in the project through its employee benefit program. In addition to this, to expand the activity beyond the company, Panasonic will begin utilizing crowdfunding this April to enable anyone who shares the spirit of this campaign to participate by pledging a small amount of money.

Ms. Rika Fukuda, General Manager, CSR & Citizenship Group of Panasonic, which led the project, said: "We are very pleased to achieve the 100,000 goal. As a global corporate citizen, we remain committed to helping people living without electricity solve problems, with the aim to build an inclusive society where everyone enjoys life by sharing the joy with each other." The company will also continue contributing to SDGs through activities that utilize its business, she added.

Summary of activities
Major Outcomes of the Project Contributing to the UN’s SDGs
1. “Affordable and clean energy”
- Reduced use of kerosene lamps by 37.7% (Myanmar)
2. “Good health and well-being”
- 2,434 children born in rooms well-lit by lanterns (Myanmar)
3. “Quality education”
- 100% pass rate in school tests for progressing to next academic level (Myanmar)
4. “Gender equality”
- Approximately 40% increase in income due to increased opportunities for women such as working at night (India)
5. “No poverty”
- Fuel costs for kerosene lamps are reduced by 50% per month (Cambodia)

Sustainable Development Goals
Sustainable Development Goals are a set of goals adopted by countries at a special United Nations summit in September 2015 for the period from 2016 to 2030. The SDGs comprise of 17 goals and 169 targets aimed at realizing sustainability, and it is the UN's intention that no one should be left behind. The SDGs are universal, and require the combined effort from all nations, developing and advanced.

Source: http://news.panasonic.com/global/stories/2018/54520.html

Related Links

100 THOUSAND SOLAR LANTERNS PROJECT
http://panasonic.net/sustainability/en/lantern/

About the BG-BL03 solar lanterns donated to Indonesia
http://panasonic.net/sustainability/en/lantern/products.html

100 THOUSAND SOLAR LANTERNS PROJECT Facebook page
https://www.facebook.com/PanasonicSolarLantern

Panasonic's Sustainability Initiatives
https://www.panasonic.com/global/corporate/sustainability.html

Panasonic Donates 1,200 Solar Lanterns to Central Vietnam (Oct 16, 2017)
http://news.panasonic.com/global/stories/2017/51655.html

Panasonic Donates 3,060 Solar Lanterns to Humanitarian & Non-Governmental Organizations in Myanmar Bringing Total Number of Donations to 14,924 Throughout 5 Years (Sep 20, 2017)
http://news.panasonic.com/global/stories/2017/50858.html

Panasonic Donates Over 2,000 Solar Lanterns to Cambodian NPOs, Bringing Total Number of Donations to 13,516 Throughout Five Years (Aug 30, 2017)
http://news.panasonic.com/global/stories/2017/50228.html

Contact information

Panasonic Corporation
Global Communications Department
Global PR Office
Click here to go to Media Contact form

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45Tiedote

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10Tiedote

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30Tiedote

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 20:37Tiedote

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10Tiedote

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme